Brought to you by 
GSK, Theravance develop respiratory drug candidates
20 Dec 2016
Executive Summary
GlaxoSmithKline and Theravance (small-molecule drug discovery technologies) entered an agreement to develop and sell respiratory disease therapeutics, including those for asthma and chronic obstructive pulmonary disease. The deal could be worth up to £245.2mm ($395mm) to Theravance.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK, Theravance develop respiratory drug candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice